SCHEMBL459952

SCHEMBL459952

COC(=O)C(OC(C)(C)C)c1c(C)nc2c(-c3ccccc3)cnn2c1-c1cc(F)c2c(c1C)CCCO2

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1I2 O75469 1/20 0.68
KDM4E B2RXH2 3/20 0.35
ALDH1A1 P00352 2/20 0.35
L3MBTL1 Q9Y468 3/20 0.35
NPC1 O15118 3/20 0.34
RAB9A P51151 3/20 0.34
CYP3A4 P08684 1/20 0.34
MAPT P10636 2/20 0.33
ATM Q13315 1/20 0.33
HCRTR1 O43613 1/20 0.32
GAA P10253 1/20 0.32
MAPK1 P28482 1/20 0.32
ERAP1 Q9NZ08 1/20 0.32
MEN1 O00255 1/20 0.32
CASP3 P42574 1/20 0.32
BLM P54132 1/20 0.32
KMT2A Q03164 1/20 0.32
NCOA1 Q15788 1/20 0.32
SENP8 Q96LD8 1/20 0.32
SENP7 Q9BQF6 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL458872 0.94 NR1I2 (0.75) NR1I2KDM4EALDH1A1L3MBTL1NPC1
SCHEMBL461512 0.93 NR1I2 (0.60) NR1I2KDM4EALDH1A1L3MBTL1NPC1
SCHEMBL462892 0.92 NR1I2 (0.59) NR1I2KDM4EALDH1A1L3MBTL1CYP3A4
SCHEMBL10175423 0.89 NR1I2 (0.69) NR1I2CYP3A4
SCHEMBL463092 0.89 NR1I2 (0.69) NR1I2CYP3A4
SCHEMBL12091349 0.88 NR1I2 (0.68) NR1I2KDM4ECYP3A4MAPTMAPK1
SCHEMBL459580 0.88 NR1I2 (0.68) NR1I2CYP3A4MAPK1
SCHEMBL470266 0.88 NR1I2 (0.68) NR1I2ALDH1A1L3MBTL1NPC1RAB9A
SCHEMBL461693 0.87 NR1I2 (0.67) NR1I2ALDH1A1CYP3A4MAPTMAPK1
SCHEMBL456824 0.87 NR1I2 (0.67) NR1I2ALDH1A1CYP3A4MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633200-B2 Inhibitors of human immunodeficiency virus replication BRISTOL-MYERS SQUIBB COMPANY (US) 2014-01-21 US disclosed
US-8633200-B2 Inhibitors of human immunodeficiency virus replication BRISTOL-MYERS SQUIBB COMPANY (US) 2014-01-21 US disclosed
US-8633200-B2 Inhibitors of human immunodeficiency virus replication BRISTOL-MYERS SQUIBB COMPANY (US) 2014-01-21 US disclosed
EP-2614064-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION Bristol-Myers Squibb Company (US) 2013-07-17 EP disclosed
US-20120225888-A1 Inhibitors of Human Immunodeficiency Virus Replication BRISTOL-MYERS SQUIBB COMPANY 2012-09-06 US disclosed
US-20120225888-A1 Inhibitors of Human Immunodeficiency Virus Replication BRISTOL-MYERS SQUIBB COMPANY 2012-09-06 US disclosed
US-20120225888-A1 Inhibitors of Human Immunodeficiency Virus Replication BRISTOL-MYERS SQUIBB COMPANY 2012-09-06 US disclosed
WO-2012033735-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-15 WO disclosed
WO-2012033735-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225888-A1 Inhibitors of Human Immunodeficiency Virus Replication EIF2AK2, RTF2, MAVS NR1I2 3085/4885KDM4E 2143/4885ALDH1A1 3327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.